| 1.34 0.01 (0.75%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.63 | 1-year : | 1.9 |
| Resists | First : | 1.39 | Second : | 1.63 |
| Pivot price | 1.3  |
|||
| Supports | First : | 1.28 |
Second : | 1.22 |
| MAs | MA(5) : | 1.32 |
MA(20) : | 1.29 |
| MA(100) : | 1.26 |
MA(250) : | 1.42 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 57.4 |
D(3) : | 56.1 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 3.19 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RFL ] has closed below upper band by 23.0%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.35 - 1.36 | 1.36 - 1.36 |
| Low: | 1.29 - 1.29 | 1.29 - 1.3 |
| Close: | 1.33 - 1.34 | 1.34 - 1.35 |
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Wed, 22 Apr 2026
MIT grants Rafael exclusive rights for Alzheimer’s therapy in ApoE4 patients - Stock Titan
Wed, 25 Mar 2026
Lobbying Update: $24,000 of RAFAEL HOLDINGS INC. lobbying was just disclosed - Quiver Quantitative
Mon, 16 Feb 2026
AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI
Thu, 11 Dec 2025
Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results - The Chronicle-Journal
Tue, 02 Dec 2025
Rafael Holdings issues warrants in connection with Cyclo Therapeutics merger - Investing.com
Fri, 18 Jul 2025
Rafael Holdings elects Scott Fine as ex-officio director and amends bylaws - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Real Estate
|
|
|
Industry:
Real Estate - Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 3.119e+007 (%) |
| Held by Institutions | 37.8 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.445e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 154 % |
| Return on Equity (ttm) | -23.8 % |
| Qtrly Rev. Growth | 1.16e+006 % |
| Gross Profit (p.s.) | 348 |
| Sales Per Share | -82.74 |
| EBITDA (p.s.) | 2.16e+006 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.44 |
| Dividend | 0 |
| Forward Dividend | 44050 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|